Shalaks - Keresési eredmények

Európai Unió - lett - EMA (European Medicines Agency)

stelfonta

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - suņi - par attieksmi pret trešo resectable, kas nav metastātisku (kas inscenējums) zemādas tuklo šūnu audzēji, kas atrodas vai distālo līdz elkonim vai ieķīlāt, un ne-resectable, kas nav metastātisku ādas tuklo šūnu audzēji ar suņiem.

Európai Unió - lett - EMA (European Medicines Agency)

kapruvia

vifor fresenius medical care renal pharma france - difelikefalin - pruritus - visi pārējie terapeitiskie produkti - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.

Európai Unió - lett - EMA (European Medicines Agency)

spevigo

boehringer ingelheim international gmbh - spesolimab - psoriāze - imūnsupresanti - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Európai Unió - lett - EMA (European Medicines Agency)

suvaxyn csf marker

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - cūkas - lai aktīvi vakcinētu cūkas no 7 nedēļu vecuma, lai novērstu mirstību un samazinātu infekciju un slimību, ko izraisa klasiskā cūku mēra vīruss (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.